重组大鼠IgG2b同型对照抗体 | Syd Labs PA007144
Syd Labs 体内实验级重组大鼠IgG2b同型对照抗体（In Vivo Grade Recombinant Rat IgG2b Isotype Control Antibody，货号：PA007144）是用哺乳动物细胞生产的重组抗体，适用于体内和体外研究。重组大鼠IgG2b同型对照抗体小鼠可变区和大鼠 IgG2b kappa不变区，与经测试的大鼠样本的特异性结合程度低或无特异性结合。
产品参数
| 货号 | PA007144 |
|---|---|
| 产品名称 | 重组大鼠IgG2b同型对照抗体 | Syd Labs PA007144 |
| 英文名 | In Vivo Grade Recombinant Rat IgG2b Isotype Control Antibody |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 别称 | 重组大鼠IgG2b同型对照抗体，大鼠IgG2b阴性对照抗体，rtIgG2b同型对照抗体 |
| 概述 | Syd Labs 体内实验级重组大鼠IgG2b同型对照抗体是用哺乳动物细胞生产的重组抗体，适用于体内和体外研究，与经测试的大鼠样本的特异性结合程度低或无特异性结合。 |
| 克隆号 | 12B9 |
| 同种型 | 大鼠 IgG2b, kappa |
| 应用 | 用于ELISA、蛋白质印迹 (WB)、流式细胞术(Flow)、免疫沉淀(IP)、免疫组织化学(石蜡)(IHC (P))、免疫组织化学(Frozen) (IHC (F))和体内动物模型研究的大鼠IgG2b kappa抗体的同型匹配阴性对照。 |
| 免疫源 | N/A |
| 抗体形式 | 0.2 μM过滤溶液，1x PBS |
| 内毒素 | 根据 LAL 方法，≤1 EU每1mg 蛋白质 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 体内实验级重组大鼠IgG2b同型对照抗体用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。如果保存在2 至 8°C，自收到之日起可保存1个月。如果保存在-20 至 -70°C，自收到之日起可保存 12个月。 |
| 注意事项 | PA007144 Syd Labs：体内实验级重组大鼠IgG2b同型对照抗体是用哺乳动物细胞生产的重组抗体，适用于体内和体外研究，与经测试的大鼠样本的特异性结合程度低或无特异性结合。 |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
| 应用详情 | 用于ELISA、蛋白质印迹 (WB)、流式细胞术(Flow)、免疫沉淀(IP)、免疫组织化学(石蜡)(IHC (P))、免疫组织化学(Frozen) (IHC (F))和体内动物模型研究的大鼠IgG2b kappa抗体的同型匹配阴性对照。 |
文献
重组大鼠IgG2b同型对照抗体，体内实验级（In Vivo Grade Recombinant Rat IgG2b Isotype Control Antibody，货号：PA007144）
大鼠IgG2b同型对照及其突变体（天然及工程改造型rtIgG2b同型对照）可应用于多种体外、体内研究，尤其适用于动物模型的功能学研究。大鼠IgG2b抗体特性更接近小鼠IgG2a、IgG2b以及人IgG1抗体，而人IgG1也是治疗性抗体药物最常采用的亚型。多数大鼠抗体被用于研究小鼠靶蛋白。
经过Fc工程改造的IgG抗体类型越来越多，其中Fc沉默、Fc效应功能失活的抗体应用最为广泛。我方可提供Fc效应功能沉默的大鼠IgG2b同型对照抗体。
如需获取工程改造大鼠IgG2b同型对照突变体、带有Avi标签、His标签、DYKDDDDK标签的rtIgG2b同型对照及其突变体，以及生物素化rtIgG2b同型对照与突变体，请联系我们询价。大鼠IgG2b同型对照及其Fc突变体还可提供多种偶联产物（例如染料、荧光基团）。
大鼠IgG2b同型对照抗体部分参考文献：
1.Neutral ceramidase regulates breast cancer progression by metabolic programming of TREM2‑associated macrophages.
Sun, R., et al. Nat Commun. 2024 Feb 1;15(1):966. PMID: 38302493
“For the purpose of CD8+ depletion, C57BL/6J mice were injected with 200 µg/mouse of a rat anti‑CD8 antibody or rat IgG2b anti‑KLH isotype control diluted in sterile PBS, 24 h before tumor injection and every 4 days after tumor injection. …BMDMs were generated in the presence of M‑CSF or L‑929 conditional medium and pretreated with IL‑4, TCM, etomoxir, orlistat, T863 or ceramide before BMDMs were cocultured with CD8+ T cells. …For IMC, after the final DPBS wash, slides were incubated with 1:500 Cell‑ID Intercalator‑Ir (Fluidigm) in DPBS for 10 min and rinsed with MilliQ water before air‑drying overnight. …The quantity of IL‑1β, TNF‑α, IL‑22, and IFN‑γ was determined in culture supernatants, serum and tissue using ELISA kits according to the manufacturer’s instructions. …BMDMs were disrupted in RIPA lysis buffer with protease and phosphatase inhibitors (Roche) for 30 min on ice.”
2.Pharmaceutical targeting of OTUB2 sensitizes tumors to cytotoxic T cells via degradation of PD‑L1.
Ren, W., et al. Nat Commun. 2024 Jan 2;15(1):9. PMID: 38167274
“To deplete CD8+ T cells, 200 µg of InVivoMAb anti‑mouse CD8α or InVivoMAb rat IgG2b (LTF‑2, Bio X Cell, BE0090) was intraperitoneally injected 2 days before tumor cell injection, and this treatment was continued every four days until the end of the experiment. …To evaluate the efficacy of inhibitors, OTUB2‑IN‑1 was intraperitoneally injected 6 days after tumor cell injection, and this treatment was continued daily for five days. …To analyze the deubiquitination of PD‑L1 in vitro, 293T cells were cotransfected with HA‑Ub and Flag‑tagged PD‑L1. …To analyze the deubiquitination of PD‑L1 in vivo, vector control and OTUB2‑KO 293T cells were individually cotransfected with HA‑Ub and PD‑L1‑Flag or OTUB2 expression vectors. …Cleavage assays with ubiquitin‑R110, a C‑terminal derivatization of ubiquitin with R110, were performed essentially as previously described.”
3.Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas.
Hariharan, S. I., et al. Nat Commun. 2024 Jan 25;15(1):730. PMID: 38272925
“For CD4+ and CD8+ T‑cell depletion experiments, C57BL/6 mice (n = 10 mice per group) received 250 μg per dose of rat IgG2B isotype control, anti‑mouse CD4 antibody or anti‑mouse CD8 antibody intraperitoneally 4 days prior to implant. …All animal study protocols were approved by and performed in accordance with protocols approved by the MD Anderson Cancer Center (MDACC) Institutional Animal Care and Use Committees. …Images were captured using a Biorad Chemidoc MP imaging system and analyzed using ImageLab 6.1 software. …D‑2‑HG and Diacetyl‑L‑tartaric anhydride (DATAN) were from Sigma. …A set of calibrator samples in fresh media or PBS was prepared by adding appropriate amounts of pure D‑2‑HG in 0.0322 − 100 μg/mL range.”
4.A PD‑1‑targeted, receptor‑masked IL‑2 immunocytokine that engages IL‑2Rα strengthens T cell‑mediated anti‑tumor therapies.
Wu, J., et al. Cell Rep Med. 2024 Oct 15;5(10):101747. PMID: 39326410
“For immune cell depletion studies, mAbs used were as follows: mouse IgG2a isotype control (300μg) clone C1.18.4, rat IgG2b isotype control (500μg), clone LFT‑2, anti‑NK1.1 (300μg) clone PK136, anti‑CD4 (500μg) clone GK1.5, anti‑CD8 (300μg) clone 2.43. …Cytokines are potent, secreted proteins that can act in an autocrine and paracrine manner to shape immune responses. …Their immunomodulatory activities provide a strong rationale for exploring cytokine‑based therapeutics for cancer treatment. …The heterodimeric IL‑2Rβ/γ receptor binds to IL‑2 with intermediate affinity and is mostly expressed on resting CD8+ T cells and natural killer (NK) cells; the heterotrimeric IL‑2Rα/β/γ receptor binds to IL‑2 with high affinity and is primarily expressed on regulatory T cells (Tregs) and activated T cells. …An alternative approach to improve efficacy and circumvent the systemic toxicity of IL‑2 is to deliver IL‑2 signaling specifically to T cells that are tumor reactive. One cell‑surface marker upregulated on tumor‑reactive T cells is the coinhibitory receptor programmed cell death protein 1 (PD‑1).”